Darolutamide (BAY1841788)

DRUG2 trials

Sponsors

Bayer, Sir Mortimer B. Davis - Jewish General Hospital

Conditions

Castration-resistant Prostate CancerCerebrovascular CirculationMetastatic Prostate Cancer

Phase 1

Imaging Study to Compare Effects of Darolutamide and Enzalutamide With Respect to Placebo on the Blood Flow in the Brain in Healthy Male Volunteers.

CompletedNCT03704519

BayerCerebrovascular Circulation

Start: 2018-10-23End: 2019-11-05Updated: 2020-10-30

Phase 2

Management of Oligoprogressive Castration Resistant Prostate Cancer (PCS X)

Active, not recruitingNCT04070209

Sir Mortimer B. Davis - Jewish General HospitalCastration-resistant Prostate Cancer, Metastatic Prostate Cancer

Start: 2020-10-19End: 2030-11-01Updated: 2026-05-27

Related Papers

Comparison of Cerebral Blood Flow in Regions Relevant to Cognition After Enzalutamide, Darolutamide, and Placebo in Healthy Volunteers: A Randomized Crossover Trial

Targeted Oncology2023-04-2723 citations

Significant localized reduction in cerebral blood flow (CBF) in regions relevant to cognitive function with enzalutamide (ENZA) compared to darolutamide (DARO) and placebo (PBO) in healthy volunteers.

Journal of Clinical Oncology2020-02-1915 citations